Over the past decade, more men than women have shown improved outcomes from antithrombotic therapies after acute coronary syndrome (ACS), which raises the question of whether there are sex-specific differences in treatment patterns and response to therapy. Differences in presenting clinical characteristics, pathophysiologic profile, and disparities in treatment may contribute to this outcomes discrepancy. Analyses of large trials and registry data suggest that male and female ACS patients experience similar benefits from antithrombotic therapy without significant difference in treatment utilization rates, yet women are consistently at higher risk of bleeding than men. Bleeding may result in antithrombotic treatment disruption, which increases the risk of long-term thrombotic events. Additionally, female ACS patients are more likely to receive suboptimal medication dosing and have lower rates of long-term medication adherence. These differences have significant clinical implications for women, indicating the need for strategies that will optimize initial treatment and long-term management attuned to these recognized sex-specific gaps.
Introduction
According to the World Health Organization, cardiovascular disease (CVD) remains the global leading cause of death 1 and is projected to cause .23.6 million deaths by the year 2030. 2 While the overall rate of coronary artery disease (CAD)-related mortality is higher for men than for women, this difference has diminished over the last decade, as men have demonstrated a decrease in CAD-related mortality, while simultaneously, women have experienced a disproportionate increase in CAD-related mortality. 3, 4 The reasons for this observed sex-based disparity in mortality among patients presenting with acute coronary syndrome (ACS) remain poorly understood, raising the question of whether there may be sex-specific differences in baseline cardiovascular characteristics, treatment patterns, or response to treatment that contribute to this phenomenon. Antithrombotic therapy is a major treatment modality for the management of ACS and encompasses antiplatelet agents (aspirin, P2Y 12 receptor antagonists, and glycoprotein IIb/IIIa inhibitors) and anticoagulants (indirect/direct thrombin inhibitors and factor Xa inhibitors). In this article, we provide an overview of current data examining sex differences in the use of, and outcomes related to, antithrombotic therapy in the treatment of patients with ACS. We are hopeful that a better understanding of the basis for sexrelated differences in post-ACS outcomes potentially leads to more evidence-based therapeutic approaches for female and male patients presenting with ACS.
Comparison of baseline characteristics between female and male acute coronary syndrome patients
One possibility to account for the sex-specific differences in outcome from antithrombotic therapies post-myocardial infarction (MI) is that pre-existing physiological differences between men and women influence response to antithrombotic therapy. In fact, several previous studies have demonstrated variations in clinical, biological, and quality-of-life characteristics between female and male patients presenting with ACS. To begin with, there are sex differences in the timing of initial ischaemic presentation. For instance, data from the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) registry showed that women typically present with ACS 10 years later than men. 5, 6 Moreover, data from both CRUSADE and the more contemporary registry Acute Coronary Treatment and Intervention Outcomes Network Registry w -Get With The Guidelines TM (ACTION Registry-GWTG) showed that, on average, women tend to experience a longer time from symptom onset to medical evaluation compared with that in men. 6 One Dutch study observed that the time from the patient's call for help to physician consultation was 10 min longer in women than in men suspected of ACS. 7 Similarly, a Korean study of 6636 ACS patients observed that the average time lapse from symptom onset to hospital arrival was 8 h for men and 11 h for women (P , 0.001). 8 By the time of ACS presentation, women tend to be older, more likely to have comorbidities such as diabetes and hypertension, and are generally at higher risk of adverse outcomes including thrombotic and bleeding events than men. 5 In fact, in a US-based study of patients with acute MI treated with percutaneous coronary intervention (PCI), female patients were more likely to present with prior stroke, heart failure, peripheral arterial disease, and worse renal function than men. 9 When examining mortality after ACS, the Swedish Web-system for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated According to Recommended Therapies registry showed that women had a higher risk than men in terms of in-hospital mortality even after adjustment for baseline characteristic differences, 10 as well as a higher risk of developing in-hospital complications such as cardiogenic shock, heart failure, bleeding, and vascular complications; 11 these risks persisted despite women being less likely than men to have high-risk angiographic features or high-grade stenosis among those evaluated with coronary angiography. 12 These differences in age, timing of symptom onset, and preexisting comorbidities at the time of ACS occurrence may point to underlying sex-specific biological variations affecting thrombosis risk. 13 Several studies have hypothesized that a pleiotropic hormonal effect, in combination with platelet hyperactivity, can induce metabolic and vascular changes that lead to faster atherosclerotic progression in post-menopausal women than in men. 14 The delayed onset and more rapid progression of atherosclerosis in postmenopausal women may in part be explained by the loss of the endothelial protective effect of oestrogen after menopause, resulting in endothelial dysfunction that speeds atherosclerotic progression. Consistent with this hypothesis, Becker et al. showed that compared with men, women had consistently more reactive platelets in response to aspirin therapy in both whole blood and platelet-rich plasma. 15 Yet whether these differences in platelet reactivity are clinically significant remain unclear, since a separate study showed no sex differences in several composite endpoints (including all-cause death, occurrence of ischaemic symptoms with elevated cardiac biomarkers, and number of definite stent thrombosis events and ischaemic stroke events) even though women had a higher baseline platelet count and exhibited a higher magnitude of platelet reactivity on aspirin and clopidogrel. 16 Moreover, key demographic and psychosocial characteristics also differ between male and female ACS patients. On the basis of the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome study, 9 which examined ST-segment elevation MI (STEMI) and non-STEMI (NSTEMI) patients treated with PCI, women were more often of non-white race, unmarried, or unemployed than their male counterparts. In terms of functional characteristics, women scored lower on all EuroQoL-5 Dimension domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and were more likely to report symptoms of depression and lower quality-of-life scores than men.
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Men and women show similar efficacy from antithrombotic therapies
Despite the differences in pre-existing biological characteristics between men and women presenting with ACS, it is unknown whether these variances translate into differences in antithrombotic therapy efficacy. Recent studies appear to show largely equivalent efficacy of antithrombotic treatment for ACS between men and women.
In a meta-analysis of five major antiplatelet therapy trials, it was found that clopidogrel significantly reduced the risk of MI, but also increased bleeding risk (regardless of patient sex) when compared with placebo. Notably, there were no significant sex differences in cardiovascular mortality with the use of clopidogrel. 18 The Platelet
Inhibition and Patient Outcomes (PLATO) trial showed that ticagrelor significantly reduced mortality rates compared with clopidogrel in ACS patients, but in pre-specified subgroup analyses, found no significant sex differences in the absolute and relative reductions of adverse cardiovascular events with ticagrelor compared with clopidogrel at 1 year (interaction P-value 0.78) and all-cause death (interaction P-value 0.49). 19, 20 With prasugrel, the mortality risk for women with confirmed epicardial CAD was at least as high as that for men following unstable angina, STEMI, or NSTEMI. The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38 was the only study that showed prasugrel to have greater absolute (2.4 vs. 1.6%) and relative (21 vs. 12%) reductions in major adverse cardiovascular events in men than women when compared with clopidogrel. 21 Additionally, a German study compared the clinical outcome of women and men presenting with STEMI undergoing primary PCI with concomitant use of glycoprotein IIb/IIIa inhibitors and found that female sex did not emerge as an independent predictor of major adverse cardiovascular events. 22 When considered together, these studies indicate that sex is not a major differentiator of antiplatelet efficacy in the management of ACS. With regard to anticoagulant therapy, the use of fondaparinux was studied in the Fifth and Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trials, and there were no sex differences in clinical outcomes found between fondaparinux and unfractionated heparin. 23 For bivalirudin, the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial demonstrated that women with NSTEMI undergoing PCI had similar 30-day composite ischaemic complications compared with men, despite the fact that female enrolees in the trial were older and had more comorbidities. 24 Furthermore, no significant sex interaction was observed when comparing bivalirudin vs. heparin therapy and glycoprotein IIb/IIIa among STEMI patients in the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction study. 25 In summary, there has been no evidence to date of sex differences in anticoagulant therapy effectiveness.
Women are consistently at higher risk of bleeding than men
Nevertheless, female sex has consistently been associated with increased risk-adjusted bleeding among ACS patients 26, 27 ( Figures 1   and 2) . Notably, in the CRUSADE bleeding score, 27 female sex is one of eight significant and independent predictors of in-hospital major bleeding. This bleeding risk includes both nuisance bleeding (e.g. Bleeding Academic Research Consortium Type 1) and bleeding of worse severity. 9 A CRUSADE registry analysis showed higher rates of in-hospital major bleeding in women than in men; this includes those treated with glycoprotein IIb/IIIa inhibitors (15.7 vs. 7.3%, P , 0.001), as well as those not treated (8.5 vs. 5.4%, P , 0.0001). 26 Similarly, a recent Italian study observed that women with ACS undergoing coronary angiography and PCI experience a significantly higher incidence of in-hospital bleeding than their male counterparts. 29 Studies have also observed sex-based differences in the locations most prone to bleeding after catheterization. In women, the majority of bleeding observed after PCI was related to the vascular access site, whereas complications in men were largely related to gastrointestinal bleeding. 35 Local anatomical differences may contribute to a greater risk of access site bleeding among women undergoing invasive coronary procedures; consistent with this, a German study showed that women had a two-fold increase in access site bleeding compared with men, but no significant difference was observed for non-access site bleeding. 34 Data from a British study further supported these observations, revealing that the use of transradial access for PCI, compared with transfemoral access, resulted in a decrease in the rate of bleeding events in men and women, but particularly among women. 36 While women have a higher observed risk of bleeding compared with men, the interaction of gender with the effect of antithrombotic therapy on bleeding remains less clear. In reviewing data from randomized controlled trials and registries over the past 15 years, there appears to be a discrepancy in findings of sex-based differences in bleeding risk conferred by antithrombotic therapies. While large registry studies such as CRUSADE showed that women were more likely than men to experience bleeding complications from antithrombotic therapy, 26 the authors of the ACUITY trial observed no significant interaction between sex and the effects of antithrombotic therapy with respect to bleeding risk at 1 year. 37 18 showed no significant interactions between sex and antithrombotic therapy with regard to bleeding risk. This Figure 1 Sex-based differences in major adverse cardiovascular events*. This figure displays the sex-based differences in major adverse cardiovascular events. *This figure contains references.
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Sex-specific benefits and risks discrepancy between clinical trial subgroup analysis and observational registry analysis results may partially be due to an underrepresentation of women in clinical trials. 38 Another explanation may be the proclivity towards excess dosing among female patients when treated with antithrombotic therapy in routine practice, which is attributed to inaccuracies in either weight-based or renal function-based dosing.
Sex-based differences in acute coronary syndrome management and outcomes
What may account for the higher bleeding risk in women compared with men despite equivalent efficacy and response to antithrombotic therapy? One reason for the higher bleeding risk among women may be that women have an increased propensity to be given higher antithrombotic doses than men. For instance, several studies showed that during the course of ACS care, women are not only more likely to receive excess dosing of any antithrombotic agent, but are more likely to receive excess dosing of multiple antithrombotic agents. 26, 39 The observation that women were more likely than men to receive different medications and dosing suggests that perceived differences in antithrombotic response may contribute to observed sex disparities in ACS management. For example, female ACS patients are more likely than males to be treated with conservative, non-invasive management. 22 Even among STEMI patients, women were less likely than men to receive reperfusion. 28 These disparities have not diminished with time. In a study of four registries spanning a decade, women with ACS were consistently less likely than men to be treated with coronary angiography inhospital and had higher in-hospital mortality. 40 In the CRUSADE registry, women were not only less likely than men to receive coronary artery bypass grafting or PCI, 41 but were less likely to receive antithrombotic therapy despite having higher risk profiles. 5 Significant sex differences in long-term adherence to evidencebased medication have also been observed, which may further contribute to disparities in bleeding risk from antithrombotic therapy. In a study of consecutive MI patients in the Duke Databank for Cardiovascular Disease, female sex was associated with lower long-term medication adherence to aspirin, angiotensin-converting enzyme inhibitors, and lipid-lowering therapies. 42 Similarly, the Patterns of Nonadherence to Antiplatelet Regimens in Stented Patients registry reported that in patients undergoing PCI and discharged on antiplatelet agents, higher rates of nonadherence were observed in women compared with men. At 1-year post-discharge, more women than men ceased antiplatelet therapy due to physician-recommended discontinuation (11.2 vs. 9.5%, P ¼ 0.09), disruption [due to noncompliance or bleeding (10.7 vs. 7.8%, P ¼ 0.001)], and interruption [for surgery (5.5 vs. 4.3%)]. 43 Among patients who develop bleeding, antiplatelet therapy was more often temporarily discontinued in men than in women, 44 even for minor bleeds. 45 Importantly, 43% of post-discharge bleeding events were never brought to clinical attention and 28% of changes to antiplatelet therapy in response to bleeding were made without a cardiologist's involvement. 44 These findings underscore the importance of close clinical monitoring to permit early recognition of bleeding complications to avoid premature antithrombotic discontinuation.
The significantly higher bleeding rates in female ACS patients may underscore the recommendation for use of bleeding risk prediction tools to guide treatment strategies, particularly for the consideration of bleeding avoidance strategies, such as radial artery access or arterial closure devices. Additionally, since many of the antithrombotic therapies have similar effectiveness for men and women, estimated bleeding risks can help drive the selection of antithrombotic treatment options for women. In terms of treatment, a greater awareness of sex-based differences can guide intensity of monitoring by healthcare providers. Although women are managed with the same pharmacological therapy as men, closer attention should be paid to avoid excess dosing by measuring actual body weights and calculating weight-adjusted creatinine clearance among female patients.
Future directions
To date, the pathophysiologic reasons for the observed bleeding disparities between men and women remain unclear. In order to better understand sex differences in antithrombotic therapy use and associated outcomes, more women need to be represented in major clinical trials ( Table 1) . On average, among 801 198 patients enrolled in 156 cardiovascular trials, only 30.6% were women and only one-third of the trials reported sex-specific results. 38 One possible explanation for this disparity is that within the age range most likely to be included in clinical studies, there is a substantially higher prevalence of symptomatic CAD in men than women. Nevertheless, female sex is significantly associated with non-participation in clinical trials among screened and eligible patients. 49 The under-representation of women in clinical trials warrants further attention, both to ascertain causes of lower female study enrolment and to target actions that effectively improve female representation in clinical trials contributing to treatment recommendations. 
Conclusions
Data from studies presented in this article suggest that sex-based differences exist in the pathophysiology and clinical presentation of MI. Recommended antithrombotic therapies for acute MI are similar in efficacy for males and females, but females are consistently at higher risk of bleeding complications. The evident sex disparities in the management and outcomes of ACS patients warrant novel personalized approaches to antithrombotic therapy selection that optimize the balance between treatment benefit and risk.
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